mRNA Technology Newsletter
Issue #17December 29, 20257 studies

mRNA flu vaccines work in newborn primates — and an AI-designed herpes vaccine shows promise in mice

The mRNA revolution is expanding beyond COVID-19, with researchers testing everything from herpes vaccines to obesity treatments. This week brought major advances in vaccine design and delivery systems that could reshape how we prevent disease.

🐒 Influenza mRNA vaccine protects newborn primates

  • Newborn nonhuman primates vaccinated with an influenza mRNA vaccine showed robust antibody responses and significantly reduced viral loads when challenged with the virus

  • The vaccine induced multi-functional antibodies that provided protection in this vulnerable age group, which typically has altered immune systems

  • Currently, no influenza vaccines are licensed for human infants under 6 months of age, leaving this high-risk population unprotected

Why it matters: This could address a critical gap in vaccine coverage for the most vulnerable population—newborns experience higher hospitalization and mortality rates from influenza than older children.

🥉 Top 5% journal 🔗 NPJ vaccines Journal Article 🗓️ Dec 26

Key Findings

🤖 AI helps design promising herpes vaccine

  • An AI-assisted pipeline identified a promising mRNA vaccine candidate targeting herpes simplex virus 2 (HSV-2) that provided full protection from genital disease in mice

  • The quadrivalent vaccine (targeting 4 viral proteins) generated high neutralizing antibody titers and strong T cell responses that lasted at least 16 weeks

  • Vaccinated mice showed significantly reduced viral DNA in genital tracts and markedly lower HSV-2 DNA levels in nerve tissue where the virus establishes latency

💡 AI-guided vaccine design may accelerate development of vaccines for diseases that have long resisted traditional approaches.
🥉 Top 5% journal 🔗 Frontiers in immunology Comparative Study 🗓️ Dec 22

🎯 New platform eliminates need for lipid nanoparticles

  • The "Gemini" platform uses self-amplifying RNA that doesn't require lipid nanoparticle encapsulation, simplifying manufacturing and storage

  • A single-dose SARS-CoV-2 vaccine based on this platform induced potent immune responses and maintained stability during freeze-thaw cycles and ambient temperature storage

  • The system supports larger and more complex genetic payloads than conventional mRNA vaccines while exhibiting enhanced stability

💡 Eliminating complex manufacturing requirements could make mRNA vaccines more accessible in resource-limited settings.
🥈 Top 2% journal 🔗 Nature communications Journal Article 🗓️ Dec 22

🧬 Peptide system offers safer mRNA delivery

  • A new peptide-based delivery system (HBpep-SS4) achieved >95% mRNA encapsulation and successfully delivered large RNA molecules up to 9,700 nucleotides

  • The system enabled 86% gene editing efficiency when delivering CRISPR components and bypassed problematic endosomal trafficking pathways

  • Unlike lipid nanoparticles, this approach disassembles in cellular environments without producing toxic byproducts

💡 Peptide-based alternatives may reduce the safety concerns associated with current lipid nanoparticle systems.
🥈 Top 2% journal 🔗 ACS nano Journal Article 🗓️ Dec 26

💉 Ultra-low dose rabies vaccine shows complete protection

  • A self-amplifying RNA rabies vaccine provided 100% survival in mice at just 0.1 μg—15-fold lower than previously reported effective doses

  • Single vaccination achieved complete protection within 14 days, while a two-dose schedule reduced the required dose by 80% to just 0.02 μg

  • The vaccine induced high-titer neutralizing antibodies and robust T-cell activation at these ultra-low doses

💡 Dose-sparing vaccines could dramatically reduce manufacturing costs and improve access in regions where rabies kills 59,000 people annually.
Top 20% journal 🔗 Vaccine Journal Article 🗓️ Dec 27

🫁 Cystic fibrosis treatment restores lung function

  • LUNAR lipid nanoparticles delivering CFTR mRNA restored ion transport in cystic fibrosis patient cells to levels comparable to the leading drug elexacaftor/tezacaftor/ivacaftor

  • A single dose improved mucociliary clearance by 3-fold in cystic fibrosis ferrets, a key measure of lung function

  • The treatment increased CFTR-mediated salt transport from airways of treated ferrets, indicating functional protein restoration

💡 mRNA therapy could provide an alternative to expensive daily medications for the 70,000 people worldwide with cystic fibrosis.

🏭 High-throughput platform accelerates vaccine discovery

  • A new automated microfluidic platform can generate 1,000 distinct lipid nanoparticle formulations per hour, dramatically speeding vaccine development

  • The system uses 8 parallel microscale mixers with precisely controlled flow ratios and integrates robotic sample collection

  • Researchers characterized 96 formulations for both physical properties and biological activity, identifying lead candidates that matched state-of-the-art performance

💡 Automated screening could compress vaccine development timelines from years to months by rapidly testing thousands of formulation variants.
🥈 Top 2% journal 🔗 ACS nano Journal Article 🗓️ Dec 26

Implications

These advances suggest mRNA technology is maturing beyond COVID-19 vaccines into a versatile platform for treating genetic diseases, preventing challenging infections, and even targeting obesity. The combination of AI-guided design, improved delivery systems, and high-throughput screening could dramatically accelerate the development of personalized medicines.

Studies in this issue

Primary sources used for this newsletter.

  1. An mRNA flu vaccine produces strong immune responses in newborn primates that improve protection against infection
    main storyNPJ vaccines2025-12-26PMID 41453893
  2. A two-part self-boosting system for vaccines and nanomedicines without lipid nanoparticles
    key findingNature communications2025-12-22PMID 41430043
  3. Peptide-Based Capsules That Respond to Cell Chemistry for Better mRNA Delivery and Release Inside Cells
    key findingACS nano2025-12-26PMID 41451635
  4. LUNAR® nanoparticle delivery of CFTR mRNA restores channel function and improves mucus clearance in human and ferret cystic fibrosis airways
    key findingMolecular therapy : the journal of the American Society of Gene Therapy2025-12-25PMID 41445193
  5. Automated Microfluidic Production of Large, Well-Controlled Lipid Nanoparticle Collections
    key findingACS nano2025-12-26PMID 41453807
  6. Design and immune response of a four-part mRNA vaccine against HSV-2 comparing combined and mixed formulations
    key findingFrontiers in immunology2025-12-22PMID 41425559
  7. A very small dose of a self-boosting RNA rabies vaccine quickly protects mice completely
    key findingVaccine2025-12-27PMID 41455183

Continue reading

All mRNA Technology issues